The 2010 patent landscape for spleen tyrosine kinase inhibitors +

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 2, 2012, Pages 97-120

  Moretto, Alessandro F ^a   Dehnhardt, Christoph ^a   Kaila, Neelu ^a   Papaioannou, Nikolaos ^a   Thorarensen, Atli ^a  

^a PFIZER INC   (United States)

Author keywords

Anti inflammatory pathway; Non receptor tyrosine kinase; Rheumatoid arthritis; Syk; Syk inhibitor; Syk patents

Indexed keywords

1,6 NAPHTHYRIDINE DERIVATIVE; 2 PYRIMIDINEAMINE DERIVATIVE; 3 ANILINE 2 CARBOXAMIDOQUINOXALINE DERIVATIVE; AMIDE; AMINOPYRIMIDINE DERIVATIVE; AMINOTRIAZOLOPYRIDINE DERIVATIVE; AURORA B KINASE; BAY 61 3606; BETAMETHASONE VALERATE; BRUTON TYROSINE KINASE; CD135 ANTIGEN; DEXAMETHASONE; IMIDAZOPYRAZINE DERIVATIVE; JANUS KINASE 2; JANUS KINASE 3; OXAPROZIN; PHENYLAMINOPYRIMIDINE 2 THIAZOLE DERIVATIVE; PHTHALOZINONE DERIVATIVE; POLO LIKE KINASE 1; PROTEIN KINASE LYN; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLOPYRAZINE DERIVATIVE; PYRROLOPYRIDINE DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; BRONCHOSPASM; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EAR EDEMA; ENZYME INHIBITION; HUMAN; IC 50; LUNG EDEMA; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84858651000     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312800166895     Document Type: Review

References (88)

1. Bradshaw JM. The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal 2010; 22(8): 1175-84.
2. Au-Yeung BB, Deindl S, Hsu L, Palacios EH, Levin SE, Kuriyan J, et al. The structure, regulation, and function of ZAP-70. Immunol Rev 2009; 228(1): 41-57.
3. Papp E, Tse JKY, Ho H, Wang S, Shaw D, Lee S, et al. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay. Biochemistry 2007; 46(51): 15103-14.
4. Pao LI, Famiglietti SJ, Cambier JC. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif ty-rosines in B cell antigen receptor signal transduction. J Immunol 1998; 160(7): 3305-14.
5. Majithia V, Geraci SA. Rheumatoid arthritis: Diagnosis and management. Am J Med 2007; 120: 936-9.
6. Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, et al. Unresolved issues in identifying and overcoming inadequate responses in rheumatoid arthritis: Weighing the evidence. J Rheumatol 2007; 35(81): 4-30.
7. Cohen S, Fleischmann R. Kinase inhibitors: A new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010; 22: 330-5.
8. Bajpai M. Fostamatinib, a SYK inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009; 12(13): 174-85.
9. Rigel news release. Available at: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1391043&highlight. (Accessed on: July 8, 2010).
10. Portola news release. Available at: http://www.portola.com/pdfs/Portola_syk_Ph_1_news_release_3.22.10.pdf. (Accessed on July 8, 2010).
11. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel SYK inhibitor. Clin Immunol 2007; 124(3): 244-57.
12. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a SYK kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58(11): 3309-18.
13. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Gross-bard EB, Magilavy DB, et al. An oral spleen tyrosine kinase (SYK) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363: 1303-12.
14. Singh, R., Bhamidipati, S., Masuda, E. Preparation of prodrugs of 2,4-pyrimidinediamine compounds and their use for mediating diseases via activation of Fc receptor signaling cascades. WO2006078846 (2006).
15. P. A novel SYK kinase inhibitor suitable for inhalation: R-343(?) - WO-2009031011. Expert Opin Ther Patents 2009; 19(10): 1469-72.
16. Gregor, V.E., Liu, Y., Anikin, A., Mcgee, D.P.C., Mikel, C., Mcgrath, D.E., Vavilala, G. R., Pickens, J.C., Kadushkin, A., Thi-ruvazhi, M.S., Zozulya, S., Vairagoundar, R., Zhu, T., Chu-cholowski, A., Webb, T.R., Jiang, L., Gantla, V.R., Yan, Z. Tri-cyclic compound derivatives useful in the treatment of neoplastic diseases, inflammation disorders and immunomodulatory disorders. WO2008021369 (2008).
17. Moore WJ, Richard D, Thorarensen A. An analysis of the diamino-pyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Expert Opin Ther Patents 2010; 20: 1703.
18. Weidner, M.S. Treatment of eczemas. WO2006102898 (2006).
19. Weidner, M.S. Treatment or prevention of pruritus. WO2006102899 (2006).
20. Weidner, M.S. Dermatological compositions and salts for the treatment of dermatological diseases. WO2006102900 (2006).
21. Yura, T., Concenpcio, A.B., Han, G., Marumo, M., Yoshino, H., Kawamura, N., Kokubo, T., Komura, H., Li, Y., Lowinger, T.B., Mogi, M., Yamamoto, N., Yoshida, N., Miller, S., Popp, M.A., Redman, A.M., Rodriquez, M.E., Scott, W.J., Wang, M. Imida-zopyrimidine derivatives and triazolopyrimidine derivatives. US20056911443 (2005).
22. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Naka-shima K, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicoti-namide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003; 306: 1174-81.
23. Nakashima K, Kokubo T, Shichijo M, Li YF, Yura T, Yamamoto N. A novel SYK kinase selective inhibitor blocks antigen presentation of immune complexes in dendritic cells. Eur J Pharmacol 2004; 505: 223.
24. Cywin, C.L., Jakes, S.E., Heider, J., Bobko, M.A., Des Jarlais, R.L., Player, M., Winters, M., Zhao, B. 1,6 Naphthyridines useful as inhibitors of SYK kinase. US20107678911 (2010) & US20107705151 (2010).
25. Cywin, C.L., Jakes, S.E., Heider, J., Bobko, M.A., Des Jarlais, R.L., Player, M., Rinker, J., Winters, M., Zhao, B. 1,6 Naphthyri-dines useful as inhibitors of SYK kinase. WO03057695 (2003).
26. Fiegen, D., Handschuh, S., Hobbie, S., Hoffmann, M., Kono, T., Sato, Y., Schnapp, A., Schuler-Metz, A. 4-Dimethylamino-phenyl-substituted naphthyridines and use thereof as medicaments. WO2010015518 (2010).
27. Dahmann, G, Engelhardt, H., Fiegen, D., Handschuh, S., Hobbie, S., Hoffmann, M., Kono, T., Reiser, U., Sato, Y., Schnapp, A. Substituted naphthyridines and use thereof as medicine. WO2010015520 (2010).
28. Sawa, M., Yokota, K., Moriyama, H., Shin, M., Ro, S., Cho, J. M. 2-Aminoquinoline derivative. EP2226315 (2010).
29. Bahmanyar, S., Bates, R.J., Blease, K., Calabrese, A.A., Daniel, T.O., Delgado, M., Elsner, J., Erdman, P., Fahr, B., Ferguson, G., Lee, B., Nadolny, L., Packard, G., Papa, P., Plantevin-Krenitsky, V., Riggs, J., Rohane, P., Sankar, S., Sapienza, J., Satoh, Y., Sloan, V., Stevens, R., Tehrani, L., Tikhe, J., Torres, E., Wallace, A., Whitefield, B.W., Zhao, J. Aminotriazolopyridines, compositions thereof, and methods of treatment therewith. US20100093698 (2010).
30. Davis, P.D., Moffat, D.F.C, Batchelor, M.J., Hutchings, M.C., Parry, D.M. 2-Pyrimidineamine derivatives and processes for their preparation. WO9818782 (1998).
31. Dariavach, P., Martineau, P.E.U., Villoutreix, B. Molecules inhibiting a metabolic pathway involving the SYK protein tyrosine kinase and method for identifying said molecules. WO2009133294 (2009).
32. Sunose, M., Major, J., Harrison, R.J., Freeman, J., Morel, A. Het-erocyclylaminopyrimidines as kinase inhibitors. WO2010146133 (2010).
33. Currie, K.S., Desimone, R.W., Mitchell, S.A., Pippin, D.A.I., Dar-row, J.W., Qian, X., Velleca, M., Qian, D. Certain imidazo[1,2-A]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds. US20060183746 (2006).
34. th 2010. Available at: http://www.gilead.com/pr_1441656. (Accessed on December 22, 2010).
35. Mitchell, S.A., Currie, K.S., Blomgren, P.A., Armistead, D.M., Raker, J. 6-Aryl-imidazo[L, 2-A] pyrazine derivatives, method of making, and method of use thereof. WO2009102468 (2009).
36. Mitchell, S.A., Currie, K.S., Blomgren, P.A., Kropf, J.E., Lee, S.H., Xu, J., Stafford, D.G., Harding, J.P., Barbosa, Jr. A.J., Zhao, Z. Imidazopyrazine SYK inhibitors. WO2010068257 (2010) WO2010068258 (2010).
37. Atkinson, F.L., Barker, M.D., Campos, S.A., Parr, N.J., Patel, V.K. Novel compounds. WO2006129100 (2006).
38. nd 2004. Available at: http://www.rigel.com/rigel/pr_1091415726. (Accessed on: December 22, 2010).
39. nd 2004. Available at: http://www.rigel.com/rigel/pr_1103590175. (Accessed on: December 22, 2010).
40. Atkinson, F.L., Barker, M.D., Campos, S.A., Harrison, L.A., Parr, N.J., Patel, V.K. 6-Indolyl-4-yl-amino-5-halogeno-2-pyrimidyl amino derivatives. WO2007028445 (2007).
41. Atkinson, F.L., Campos, S.A., Harrison, L.A., Parr, N.J., Patel, V.K., Vitulli, G. 1H-Indazol-4-yl-2, 4-pyrimidinediamine derivatives. WO2007085540 (2007).
42. Campos, S.A., Harrison, L.A., Parr N.J., Patel, V.K., Vitulli G. 1,1-Dioxido-2,3-dihydro-1,2-benzisothiazol-6-yl-1H-indazol-4-yl-2, 4-pyrimidinedi amine derivatives. WO2007009681 (2007).
43. Ancliff, R.A., Atkinson, F.L., Barker, M.D., Box, P.C., Daniel, C., Gore, P.M., Cuntrip, S.B., Hasegawa, M., Inglis, G.G.A., Kano, K., Miyazaki, Y., Patel, V.K., Ritchie, T.J., Swanson S., Walker, A.L., Wellaway, C.R., Woodrow, M. Pyrrolopyrimidine derivatives as SYK inhibitors. WO2007042299 (2007).
44. Gore, P.M., Patel, V.K., Walker, A.L., Woodrow, M. Pyr-rolopyrimidine derivatives as SYK inhibitors. WO2007042298 (2007).
45. Liddle J, Atkinson F, Barker M, Douault C, Garton N, Lewis H, et al. Discovery of a Highly Potent, Selective, and Orally Bioavail-able SYK Inhibitor. American Chemical Society - 32nd Annual National Medicinal Chemistry Symposium. Minneapolis, USA (2010).
46. Atkinson, F.L., Patel, V.K. Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase. WO201010097248 (2010).
47. Collingwood, S.P., Hayler, J., Le Grand, D.M., Mattes, H., Menear, K.A., Walker, C.V., Cockcroft, Z. Purine derivatives inhibitors of tyrosine protein kinase SYK. WO200109134 (2001).
48. Baenteli, R., Zenke, G., Cooke, N.G., Duthaler, R., Thoma, G., Von Matt, A., Honda, T., Matsuura, N., Nonomura, K., Ohmori, O., Umemura, I., Hinterding, K., Papageoriou, C. Pyrimidine derivatives. WO03078404 (2003).
49. Baenteli, R., Bernhard, M.C., Buehlmayer, P., Cooke, N.G., Duthaler, R., Hinterding, K., Thoma, G., Van Eis, M., Von Matt, A., Walliser, L., Zenke, G. 2,4 Di (Hetero) -Arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors. WO2005026158 (2005).
50. Baenteli, R., Bernhard, M.C., Buehlmayer, P., Cooke, N.G., Duthaler, R., Hinterding, K., Thoma, G., Van Eis, M., Von Matt, A., Walliser, L., Zenke, G. 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors. US20060247262 (2006) & US7671063 (2010).
51. Okram, B., Uno, T., Ding, Q., Liu, Y., Jin, Q., Wu, X., Che, J., Yan, F.S. Compounds and compositions as kinase inhibitors. WO2009097287 (2009).
52. Kodama, Y., Noji, S., Imamura, K., Mizojiri, R., Aoki, K., Takagi, H., Naka, Y., Ito, G., Shinoda, K., Fujiwara, A., Kurihara, K., Tanaka, M. Aminopyridine compounds having spleen tyrosine kinase (SYK)-inhibitory activity. US20107803801 (2010).
53. Hirabayashi, A., Mukoyama, H., Shiohara, H., Kobayashi, H., Terao, Y., Miyazawa, K., Misawa, K., Onoda, H. Preparation of imidazopyrimidines as tyrosine kinase inhibitors. JP2010203748 (2010).
54. Hirabayashi, A., Shiohara, H., Kobayashi, H., Terao, Y., Miya-zawa, K., Misawa, K. Preparation of triazolopyrimidines, their pharmaceutical compositions, and their use for treatment of protein tyrosine kinase-related diseases. JP2004238296 (2004).
55. Mukoyama, H., Nishimura, T., Nakayama, A., Kikuchi, S., Koma-tsu, Y., Onoda, H. Preparation of imidazol[1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases. JP2005089352 (2005).
56. Mukoyama, H., Shiohara, H., Nishimura, T., Nakayama, A., Kiku-chi, S., Komatsu, Y., Onoda, H. Pyrazolo[1,5-a]pyrimidine derivatives, prophylactic or therapeutic agents containing them for protein tyrosine kinase-related diseases, and combination drugs containing them. JP2005008581 (2005).
57. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Naka-yama S, Ozawa M, et al. A novel SYK family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorg Med Chem 2008; 16(15): 7347-57.
58. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Naka-yama S, Ozawa M, et al. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective SYK family kinase inhibitors. Bioorg Med Chem 2008; 16(20): 9247-60.
59. Hisamichi H, Naito R, Toyoshima A, Kawano N, Ichikawa A, Orita A, et al. Synthetic studies on novel SYK inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 2005; 13(16): 4936-51.
60. Siddiqui, M.A., Belanger, D., Dai, C., Zhao, L. Preparation of heterocycles, in particular N-substituted quinolinecarboxamides, as kinase, especially ZAP-70 and SYK tyrosine kinase, and IL-2 production inhibitors. WO2004080463 (2004).
61. Dubois, D.J., Hendricks, R.T., Hermann, J.C., Kondru, R.K., Lou, Y., Owens, T.D., Yee, C.W. Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US20090215724 (2009).
62. Elworthy, T.R., Hendricks, R.T., Kondru, R.K., Lou, Y., Owens, T.D., Soth, M., Yang, H. Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US20090215788 (2009).
63. Bamberg, J.T., Bartlett, M., Dubois, D.J., Elworthy, T.R., Hen-dricks, R.T., Hermann, J.C., Kondru, R.K., Lemoine, R., Lou, Y., Owens, T.D., Park, J., Smith, D.B., Soth, M., Yang, H., Yee, C.W. Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US20090215750 (2009).
64. Dubois, D.J., Elworthy, T.R., Hendricks, R.T., Hermann, J.C., Kondru, R.K., Lou, Y., Owens, T.D., Smith, D.B. Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US20090215785 (2009).
65. Goldstein, D.M., Rueth, M. Methods of inhibiting BTK and SYK protein kinases using (pyrazolylamino)phthalazines and their preparation. US20070219195 (2007).
66. Cox, P.J., Majid, T.N., Lai, J.Y.Q., Morley, A.D., Amendola, S., Deprets, S., Edlin, C. Preparation of azaindoles as protein kinase inhibitors. WO2001047922 (2001).
67. Oligino, T., Hahn, C., Gillespy, T.A., Dharanipragada, R., Matzkin, E. Use of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]pro-pan-2-ol for the treatment for ocular-related disorders. WO2009114373 (2009).
68. Hahn, C.S. Method for treating macular degeneration using SYK multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. WO2010080563 (2010).
69. Oligino, T., Gillespy, T.A., Dharanipragada, R., Allen, E.M. Treatment for glomerulonephritis with 2-4-(-7-ethyl-5h-pyrrolo[2,3-b]-pyrazin-6-yl)propan-2-ol. WO2010065571 (2010).
70. Gillespy, T.A., Eynott, P., Allen, E.M., Yu, K.T., Zilberstein, A. Preparation of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol as a SYK kinase inhibitor. WO2008033798 (2008).
71. Lee, G.E., Shrimp, F.L. II., Weiberth, F.J. Improved chemical synthesis of diazaindoles by Chichibabin cyclization. WO2010107969 (2010).
72. Bordeau, K.J., Langevin, B.C., Lee, G.E., Logue, P., Secord, E., Sherer, D. Crystalline forms of 2-[4-(7-ethyl-5H-pyrrolo [2,3-b]pyrazin-6-yl)-phenyl]-propan-2-ol. WO2010065690 (2010).
73. Cox, P.J., Majid, T.N., Amendola, S., Deprets, S.D., Edlin, C., Pedgrift, B.L., Halley, F., Edwards, M., Baudoin, B., Mclay, L.M., Aldous, D.J. Preparation of pyrrolopyrimidines as protein kinase inhibitors. WO03000695 (2003).
74. Edwards, M.L., Cox, P.J., Amendola, S., Deprets, S.D., Gillespy, T.A., Edlin, C.D., Morley, A.D., Gardner, C.J., Pedgrift, B., Bouchard, H., Babin, D., Gauzy, L., Le Brun, A., Majid, T.N., Reader, J.C., Payne, L.J., Khan, N.M., Cherry, M. Preparation of benzimidazoles and analogs and their use as protein kinase inhibitors. WO03035065 (2003).
75. Farmer LJ, Bemis G, Britt SD, Cochran J, Connors M, Harrington EM, et al. Discovery and SAR of novel 4-thiazolyl-2 pheny-laminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 2008; 18: 6231-5.
76. th National Meeting. Washington, DC, USA (2009).
77. Brenchley, G., Farmer, L.J., Harrington, E.M., Knegtel, R., O'Don-nell, M., Salituro, F.G., Studley, J.R., Wang, J. Thiazoles useful as inhibitors of protein kinases. WO2004087699 (2004).
78. Farmer, L.J., Harrington, E.M., Salituro, F.G., Wang, J. Preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases. WO2004087698 (2004).
79. Harrington, E., Wang, J., Cochran, J., Nanthakumar, S. Preparation of thiazole compounds as inhibitors of protein kinases. WO2004096905 (2004).
80. Bemis, G.W., Duffy, J.P. Preparation of substituted quinoxalines as inhibitors of protein kinases. WO2005056547 (2005).
81. Jimenez, J.M., Green, J., Gao, H., Moon, Y.C., Brenchley, G., Knegtel, R., Pierard, F. Preparation of aminopyrimidine derivatives as inhibitors of protein kinases. US20050148603 (2005) & WO2005037843 (2005).
82. Pierce, A.C., Arnost, M., Davies, R.J., Forster, C.J., Galullo, V., Grey, R., Ledeboer, M., Tian, S.K., Xu, J., Binch, H., Ledford, B., Messersmith, D., Nanthakumar, S., Jayaraj, A. Preparation of 3,5-diamino[1,2,4]triazoles as protein kinase inhibitors. WO2004046120 (2004).
83. Binch, H., Fraysse, D., Robinson, D. Preparation of diaminotria-zoles as inhibitors of protein kinases. WO2006050249 (2006).
84. Davies, R.J., Arnost, M.J., Bemis, G.W., Forster, C.J., Grey, R. Jr., Ledford, B., Marhefka, C., Messersmith, D., Pierce, A. C., Salituro, F., Wang, J. Preparation of aminotriazole compounds useful as inhibitors of protein kinases. WO2005013982 (2005).
85. Green, J., Aronov, A., Pierce, A.C. Preparation of substituted chromen-4-one oximes as inhibitors of protein kinases. US20040198750 (2004).
86. Aronov, A., Lauffer, D.J., Li, H.Q., Tomlinson, R.C., Li, P. Preparation of indazolinone compositions useful as kinase inhibitors. WO2004037814 (2004).
87. Hisamichi, H., Kawazoe, S., Tanabe, K., Ichikawa, A., Orita, A., Suzuki, T., Onda, K., Takeuchi, M. Preparation of novel heterocyc-lic carboxamide derivatives as spleen tyrosine kinase inhibitors. WO00075113 (2000).
88. th National Meeting. New York, USA (2003).